Community Service: How Joshua J. Joseph, MD, MPH, Is Leveling the Healthcare Playing Field for All
Author: Derek Bagley
Type of Weight Loss Surgery Women Undergo Before Pregnancy May Influence Children’s Weight Gain
The type of weight loss surgery women undergo before becoming pregnant may affect how much weight their children gain in the first three years of life, according to a study presented at ENDO 2024. Researchers found children born to women who underwent sleeve gastrectomy before they became pregnant gain more weight per month on...
Childhood Sedentariness May Cause Premature Liver Damage in Young Adulthood
Children who are sedentary for more than six waking hours a day have a significantly increased risk of severe fatty liver disease and liver cirrhosis by young adulthood, according to a study presented at ENDO 2024 and published in Nature’s npj Gut and Liver. “We found that this relationship between sedentariness and liver damage is likely...
Full Circle: Q&A with New Endocrinology Editor-in-Chief, Zane Andrews, PhD
Meet New Endocrine Society President, John Newell-Price, MD, PhD
Body Positive: A Closer Look at BMI Criteria for Gender-Affirming Surgery
Body mass index (BMI) requirements for gender-affirming surgeries can sometimes present an obstacle to gender transition surgery for many transgender and gender diverse people. Sean Iwamoto, MD, and John M. Taormina, MD, two of the authors of a recent Journal of Clinical Endocrinology & Metabolism paper, discuss the need for a multidisciplinary approach for these...
Five abstracts from Crinetics Pharmaceuticals’s clinical development programs, including four late-breaking abstracts, will be presented at the Endocrine Society’s annual meeting, ENDO 2024, taking place June 1-4, 2024 in Boston – including initial data from a Phase 2 Trial of atumelnant in congenital adrenal hyperplasia (CAH). “This year’s Endocrine Society meeting represents a major milestone for...
Neurocrine Biosciences, Inc. and Diurnal Ltd., a Neurocrine Biosciences company, in May presented baseline data from the CAHtalyst™ Phase 3 studies of crinecerfont in adult and pediatric patients with congenital adrenal hyperplasia (CAH), and modified-release hydrocortisone (Chronocort®) data for a Phase 2 clinical study (CHAMPAIN) in participants with primary adrenal insufficiency and in a Phase 3 extension study in...